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ABSTRACT: Temporal lobe epilepsy (TLE) is the most common
form of partial epilepsy and affects 40% of the patients. Seizures
arising from the mesial temporal lobe structures (i.e., amygdala and
hippocampus) are common, whereas neocortical seizures are rare.
In recent years, many studies aimed to identify the pattern of gene
expression of neurotransmitters involved in molecular mechanisms of
epilepsy. We used real-time PCR to quantify the expression of
GABAA (subunits a1, b1, b2) and NMDA (subunits NR1, NR2A, and
NR2B) receptor genes in amygdalae of 27 patients with TLE and 14
amygdalae from autopsy controls. The NR1 subunit was increased in
patients with epilepsy when compared with controls. No differences
were found in expression of NMDA subunits NR2A and NR2B or
in a1, b1, and b2 subunits of GABAA receptors. Our results
suggest that the NR1 subunit of NMDA receptors is involved in the
amygdala hyperexcitability in some of the patients with TLE. VC 2010
Wiley Periodicals, Inc.
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INTRODUCTION
TLE is the most common form of partial epilepsy. It affects 40% of
the patients in adult series, and seizures arising from the mesial temporal
lobe structures (i.e., amygdala and hippocampus) are the most common
type (Babb and Brown, 1986; Hauser, 1992; Bertram, 2009). Several
studies have demonstrated that mesial temporal sclerosis (MTS) is the
most frequent histological ﬁnding in patients with
mesial TLE (MTLE), and most of them suggested
that cell loss and gliosis in speciﬁc subﬁelds of the
hippocampus were the most distinctive histological
feature (Feuerstein and Hertting, 1986; Andrade and
Nicoll, 1987). Most studies using depth electrodes
support the notion that the hippocampus is involved
in seizure generation in patients with MTLE. How-
ever, other studies suggested that the amygdala may
also be involved in the epileptogenic process in
MTLE (Lindvall et al., 1984; Holland and Gallagher,
1993; Kokaia et al., 1994a,b; Elmer et al., 1996;
Bengzon et al., 1999; Aroniadou-Anderjaska et al.,
2008; McIntyre and Gilby, 2008). In MTS for exam-
ple, a reduced volume of amygdala is believed to fol-
low the reduction of the volume of the hippocampus
(Bernasconi et al., 2005). Furthermore, studies have
shown that up to 30% of seizures in MTLE originate
from amygdala (Wennberg, 2002), but not much is
known about the mechanisms of hyperexcitability and
seizure generation in these patients.
One hypothesis that has been proposed to explain
the pathogenic mechanism of epileptogenesis is the
imbalance between excitatory and inhibitory neuro-
transmitters, which has been shown to result in
reduced seizure threshold (Neder et al., 2002; Stein-
hauser and Seifert, 2002; Avanzini and Franceschetti,
2003). Glutamate is the major excitatory neurotrans-
mitter (Moldrich et al., 2003), and several studies
have shown the role of glutamate receptors, particu-
larly the ionotropic N-methyl-D-aspartate (NMDA)
receptor, in epilepsy. In fact, studies in human epilep-
tics have shown an increased expression of NMDA re-
ceptor 1 (NMDAR1) transcript in the remaining hip-
pocampal neurons (Mathern et al., 1997; Neder et al.,
2002).
We used real-time polymerase chain reaction
(q-PCR) to quantify the expression of GABAA (a1,
b1, b2) and NMDA (NR1, NR2A, and NR2B) sub-
unit genes in 27 amygdalae of patients with temporal
lobe epilepsy. Similar to what has been shown in
the human hippocampus, we hypothesized that there
is an imbalance between excitatory and inhibitory
neurotransmission in the amygdalae of patients with
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MTLE, which may contribute to hyperexcitability and seizure
generation.
PATIENTS AND METHODS
The study was conducted at the University of Sa˜o Paulo,
Ribeira˜o Preto-Brazil, and patients were enrolled from 2002 to
2004. The follow-up ranged from 42 to 66 months. Patients
were considered eligible if they had a medical history, seizure
semiology, routine outpatient interictal EEG (electroencepha-
lography), and MRI consistent with refractory MTLE-HS
(mesial temporal lobe epilepsy with hippocampal sclerosis).
The clinical picture usually consisted of complex partial seizures
with epigastric, autonomic, or psychic auras; focal slowing,
interictal spikes, and sharp-waves over the anterior, inferior,
and mesial temporal regions on routine scalp EEG; and hippo-
campal atrophy on T1 and increased hippocampal signal on
T2 MRI sequences. Refractoriness was deﬁned as failure to
respond to at least two antiepileptic drugs. Excluded were
patients with extrahippocampal lesions, focal neurological
abnormalities on physical examination, and generalized and
extratemporal interictal spikes that were not consistent with the
MTLE syndrome or that suggested dual pathology.
The samples comprised 27 amygdalae obtained from patients
with refractory MTLE submitted to temporal lobectomy and
14 amygdalae obtained from autopsy. The amygdala samples
comprised the portion that protrudes to the ventricle cavity,
corresponding to the basolateral nucleus. In the autopsy group,
no death was caused by neurological or psychiatric disease. The
project was approved by the Research Ethics Committee of the
University Hospital, Faculty of Medicine of Ribeira˜o Preto,
University of Sa˜o Paulo.
After removal, the amygdalae were frozen in liquid N2 and
kept at 2808C until RNA extraction by the Trizol method
(Invitrogen, Carlsbad, CA) following the manufacturer’s proto-
col. The analysis of the controls and patients RNA samples was
randomized. All RNA samples were quantiﬁed by spectropho-
tometry and checked in 1% agarose gel. Complementary DNA
(cDNA) was synthesized by reverse transcription using the
commercial High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, code: 4368814) follow-
ing the manufacturer’s manual. The cDNA was ampliﬁed with
q-PCR using SYBR Green (Applied Biosystems). The sequences
of the primers for each gene are shown in Table 1.
The b-glucuronidase gene (GUSb) was used as an endoge-
nous control (housekeeping gene). We used the following PCR
conditions: preheating at 508 for 2 min, denaturation at 958
for 10 min and 50 cycles of ampliﬁcation and quantiﬁcation
(15 s at 958 and 1 min at 608). All reactions were carried out
in duplicate and analyzed with the 7,500 Sequence Detection
System apparatus (Applied Biosystems). The data were analyzed
using the ABI-7,500 SDS software. Dissociation curves were
performed (melting curves) after ampliﬁcation by q-PCR. The
samples that showed dissociation curves with different tempera-
tures and/or more than one point of dissociation in the same
sample were discarded and repeated.
Numerical variables between groups were compared with
Student’s t-tests. Signiﬁcance was set at P < 0.05. We used
GraphPad PRISM software version 4.0 for statistical analysis
(GraphPad Software Inc., San Diego, CA).
RESULTS
Clinical and Demographic Data
The clinical and demographic data of patients are shown in
Table 2. A total of 27 patients were included, and 17 were
female (63%). The mean (6SD) age of seizure onset was 6.1
(65.6) years. The seizure frequency ranged from three seizures
a day to one seizure every two months. Eighty-ﬁve percent of
patients became seizure-free after surgery.
Gene Expression
The expression level of the NMDA NR1 gene was higher in
the epileptic group when compared with the autopsy group (P
5 0.021, Fig. 1). The expression of GABAA a1, GABAA b1,
GABAA b2, NMDA NR2A, and NMDA NR2B genes are also
presented in Figure 1, but no differences were found between
groups: GABAA a1 (P 5 0.8669), GABAA b1 (P 5 0.0654),
GABAA b2 (P 5 0.9042), NMDA NR2A (P 5 0.6295), and
TABLE 1.
Primer Sequences for GABAA a1, GABAA b1, GABAA b2, NMDA NR1, NMDA NR2A, and NMDA
NR2B
Gene Primers forward (-f) Reverse (-r)
GABAA a1 ATGACGGCTGTCCATAGCTT TGGATCCTCCTTCTGAGCAC
GABAA b1 CGGAGACCATGTCTATGCTG TGGACAGATTGCTCAAAGGA
GABAA b2 TGCCTTCCATCCTGATTACC AGGTGGGTGTTGATTGTGGT
NMDA NR1 GGTACCCTCGAGGCTTCTCT GTTCGCCAACTACAGCATCA
NMDA NR2A ACCGCTGCATCTTCTATGCT AAGTCTTTGCCATCCCATGT
NMDA NR2B TCTTTGGAGATGGGGAGATG CCTGCCATGTTGTCAATGTC
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NMDA NR2B (P 5 0.5734) (Fig. 1). The mean 6 S.D. of
expression of the NMDA NR1, NMDA NR2A, NMDA
NR2B, GABAA a1, GABAA b1, and GABAA b2 genes are
presented in Table 3.
Gene Expression and Clinical Data
The expression levels of the NMDA NR1, NMDA NR2A,
NMDA NR2B, GABAA a1, GABAA b1, and GABAA b2
genes did not correlate with any of the clinical and demograph-
ical variables (seizure type, age of seizure onset, seizure fre-
quency, and postsurgical seizure outcome). Detailed results of
the expression levels for each variable are shown in Table 4.
DISCUSSION
In this study we reported the gene expression levels of the
a1, b1, and b2 subunits of the GABAA inhibitory neurotrans-
mitter receptor and the NR1, NR2A, and NR2B subunits of
the NMDA excitatory neurotransmitter receptor in human
amygdalae of 27 patients with MTLE. We found an increased
expression of NR1 mRNA in epileptic patients when compared
with controls.
Our results support the notion that temporal lobe seizures
are associated with increased expression of NMDA receptors in
the amygdala, which may contribute to neuronal hyperexcit-
ability, synchronization, and seizure generation (Mathern et al.,
1997).
Animal and human studies in hippocampus corroborate our
hypothesis that increased NR1 subunit expression can be
related to epileptogenesis (Mathern et al., 1997; Kikuchi et al.,
2000). Kikuchi et al. (2000) examined the expression level of
NMDA NR1 receptor subunit in the cerebral cortices of amyg-
daloid-kindled rats by northern blot analysis and observed a
signiﬁcant increase of NR1 mRNA expression in the ipsilateral
frontal and temporal cortices four weeks after the last general-
ized seizure. However, a signiﬁcant decrease in the expression
level of NR1 mRNA was observed in the piriform cortices.
Toro et al. (2007) used immunoautoradiography to assess NR1
NMDA receptor subunit levels in hippocampi of patients with
TABLE 2.
Clinical and Demographic Data of the MTLE Group
Patient
Gender/
age (years)
Side of
hippocampus
sclerosis
Seizure
type
Age of
onset
(years)
Seizure
frequency
ENGEL
classiﬁcation
Follow-up
(months)
1 F/42 R PS 1 G 16 1 Seizure/week I 56
2 M/40 L PS 5 1 Seizure/month III 42
3 M/34 R PS 1 G 0.5 1 Seizure/day I A 62
4 F/36 L PS 1 G 2 10 Seizures/month I A 56
5 M/58 R PS 1 G 4 5 Seizures/week I B 62
6 M/34 R PS 1 G 6 6 Seizures/day I A 66
7 M/65 L PS 7 1 Seizure/week I A 42
8 F/19 R PS 4 5 Seizures/day I D 43
9 M/43 L PS 28 5 Seizures/day I A 56
10 F/19 R PS 13 5 Seizures/week I A 63
11 F/23 L PS 6 4 Seizures/month I B 60
12 F/36 L PS 1 G 4 7 Seizures/month III 51
13 M/44 R PS 3 3 Seizures/week I A 44
14 F/31 R PS 13 20 Seizures/week I A 48
15 F/33 L PS 1 G 11 3 Seizures/week III 51
16 M/42 L PS 12 5 Seizures/day I A 44
17 F/50 L PS 1 G 3 1 Seizure/day I D 51
18 F/40 R PS 1 G 8 1 Seizure/day I A 45
19 F/34 R PS 9.5 2 Seizures/day I D 44
20 M/25 R PS1 G 13 1 Seizure/day I A 62
21 F/51 R PS 1 G 11 3 Seizures/week I A 66
22 M/32 L PS 6 3 Seizures/day I A 56
23 F/42 L PS 1 G 11 7 Seizures/month I A 66
24 F/21 L PS 5 20 Seizures/week I A 60
25 F/33 L PS 1 G 8 3 Seizures/month III 57
26 F/38 R PS 12 4 Seizures/month I D 48
27 F/23 L PS 1 G 12 10 Seizures/month I A 61
PS, partial seizure; G, generalized; M, male; F, female; R, right; L, left.
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MTLE and found no changes in epileptic patients with schizo-
phrenia-like psychosis or depression compared with controls. In
the same study, the expression of NR1 subunit-containing
NMDA receptors was higher in dysphoric and untreated
depressed patients with epilepsy. Zhu et al. (2004) observed an
increase in the expression of NR1 in the hippocampus of rats
with epileptic seizures induced by pentylenetetrazole, which
suggested that the increased expression of NMDA receptors
contributed to changes of neuronal excitability in these rats. In
contrast, using a PCR technique, Musshoff et al. (2000) did
not ﬁnd any differences in expression of the NR1 subunit in
the hippocampus or cortex of epileptic patients when compared
with nonepileptics.
Our ﬁndings for the NR2A and NR2B subunits showed no
differences between groups. Narita et al. (2000) noted an
increased expression of NR1, NR2A, and NR2B subunits in
limbic forebrains of mice using a western blotting technique.
The different results for NR1 e NR2 can be explained by the
fact that the stoichiometry of NMDA receptors is not com-
pletely understood, but most authors believe that these recep-
tors are tetramers and incorporate two NR1 and two NR2 sub-
units of the same or different subtypes. The NR1 subunit has
different isoforms, the NR2 subunit has four different isoforms
and the ﬁnal form of the receptor is highly variable. New stud-
ies of NMDA receptors considering structural aspects, pharma-
cology and binding domains will collaborate to elucidate our
ﬁnding (Paoletti and Neyton, 2007).
The distribution of glutamatergic receptors on amygdalar neu-
rons is not uniform. Sah and Lopez De Armentia (2003) found
that synapses in the central nucleus of rats activate NMDA recep-
tors that contain NR1 and NR2B subunits, whereas synapses in
the lateral nucleus contain receptors with both NR2A and NR2B
subunits. In the lateral amygdala, two distinct morphological
classes of neurons have been identiﬁed: large pyramidal-like neu-
rons, which are thought to constitute the glutamatergic projec-
tion neurons, and smaller spine-sparse neurons, which use GABA
FIGURE 1. Expression of the NMDA NR1A, NMDA NR2A, NMDA NR2B, GABAA a1,
GABAA b1, and GABAA b2 genes.
TABLE 3.
Gene Expression Levels in Epileptic and Control Groups
NMDA
NR1
NMDA
NR2A
NMDA
NR2B
GABAA
a1
GABAA
b1
GABAA
b2
Epileptics 1.42 6 0.71 1.32 6 1.12 1.11 6 0.78 0.97 6 0.51 1.27 6 0.71 1.26 6 0.88
Controls 0.82 6 0.49 1.00 6 0.83 1.14 6 0.88 1.03 6 0.71 0.97 6 0.54 1.26 6 0.89
Values are shown as mean 6 SD.
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as the primary transmitter. We could not make these inferences
in the present study because real-time PCR does not permit the
cellular localization of neurotransmitter expression.
We did not ﬁnd differences in the expression of a1, b1, or b2
subunits of GABAA receptors between groups. Generally, the
studies on the role of GABAA receptors in MTLE have utilized
immunohistochemistry and focused on the hippocampus. Bouil-
leret et al. (2000) investigated alterations in subunit architecture
and localization of GABAA receptor subtypes immunohisto-
chemically (a1, a2, a3, b2, b3, and g2) in the hippocampus
resected from MTLE patients compared with control tissue
obtained at autopsy. They found changes in GABAA receptors
with reorganization of speciﬁc receptor subtypes in some cells
and interneurons. In addition, Crino et al. (2001) found differ-
ent patterns of GABAA receptor subunit expression in cortical
dysplasia. Using immunohistochemistry, the authors observed a
decrease in the expression of the b1 subunit in dysplastic neurons
compared with pyramidal and heterotopic neurons. They also
observed a reduction in the expression of GABAA receptor a1,
a2, and b2 subunits in both dysplastic and heterotrophic
neurons.
Ion channel dysfunction is the key to the genetic human epi-
lepsies. There is increasing evidence that changes in ion chan-
nels form a common pathway for diverse causes of epilepsies
(Berkovic et al., 2006).
Our results support the notion that there are changes in
amygdala glutamate receptors in some patients with mesial
temporal lobe seizures, which may be associated with increased
neuronal hyperexcitability, synchronization, and seizures. New
studies are needed to identify those patients with MRI ﬁndings
to determine whether surgery could be tailored in response to
the need for the amygdala to be resected.
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